Dose-response study of mobilisation and tactile stimulation therapy for the upper extremity early after stroke: a phase I trial

Hunter, Susan M., Hammett, Linda, Ball, Sue, Smith, Nina, Anderson, Cheryl, Clark, Allan ORCID: https://orcid.org/0000-0003-2965-8941, Tallis, Raymond, Rudd, Anthony and Pomeroy, Valerie M. ORCID: https://orcid.org/0000-0003-4487-823X (2010) Dose-response study of mobilisation and tactile stimulation therapy for the upper extremity early after stroke: a phase I trial. Neurorehabilitation and Neural Repair, 25 (4). pp. 314-322.

Full text not available from this repository. (Request a copy)

Abstract

Physical therapy doses may need to be higher than provided in current clinical practice, especially for patients with severe paresis. The authors aimed to find the most effective and feasible dose of Mobilisation and Tactile Stimulation (MTS), which includes joint and soft-tissue mobilization and passive or active-assisted movement to enhance voluntary muscle contraction. Methods. This 2-center, randomized, controlled, observer-blinded feasibility trial compared conventional rehabilitation but no extra therapy (group 1) with conventional therapy plus 1 of 3 daily doses of MTS, up to 30 (group 2), 60 (group 3), or 120 (group 4) minutes for 14 days. The 76 participants had substantial paresis (Motricity Index [MI] < 61) a mean of 30 days (standard deviation [SD] = 20 days) after anterior circulation stroke. MTS was delivered using a standardized schedule of techniques (eg, sensory input, active-assisted movement). The primary outcome was the Motricity Index (MI) and secondary outcome was the Action Research Arm Test (ARAT) tested on day 16. Adverse events were monitored daily. Results. No difference was found in the change in control group MI compared with each of the 3 intervention groups (P = .593) or in the ARAT. Mean actual daily treatment time for all MTS groups was less than expected. The attrition rate was 1.3%. No adverse events related to overuse occurred. Conclusion. The authors were not able to deliver a maximum dose of 120 minutes of daily therapy each day. The mean daily dose of MTS feasible for subsequent evaluation is between 37 and 66 minutes.

Item Type: Article
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Faculty of Medicine and Health Sciences > School of Health Sciences
UEA Research Groups: Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research (former - to 2023)
Faculty of Medicine and Health Sciences > Research Groups > Health Services and Primary Care
Faculty of Medicine and Health Sciences > Research Groups > Norwich Clinical Trials Unit
Faculty of Medicine and Health Sciences > Research Groups > Epidemiology and Public Health
Faculty of Medicine and Health Sciences > Research Groups > Rehabilitation
Faculty of Medicine and Health Sciences > Research Centres > Population Health
Faculty of Medicine and Health Sciences > Research Centres > Lifespan Health
Depositing User: EPrints Services
Date Deposited: 25 Nov 2010 11:13
Last Modified: 19 Oct 2023 00:34
URI: https://ueaeprints.uea.ac.uk/id/eprint/15185
DOI: 10.1177/1545968310390223

Actions (login required)

View Item View Item